Warfarin sodium (Coumadin) anticoagulant Therapy for vascular access patency
Kinzner, C.L.
Anna Journal 25(2): 195-203; Quiz 204, 209
1998
ISSN/ISBN: 8750-0779 PMID: 9801498 Document Number: 493669
The increase of geriatric and diabetic patients with poor vasculature brings about a corresponding increase in the use of synthetic vascular access grafts. Synthetic vascular accesses are plagued with numerous problems in maintaining patency. As a result, many practitioners use warfarin sodium. Coumadin, because of its predictability and bioavailability to interrupt the coagulation cascade to prevent thrombus formation. This article includes actions, interactions, monitoring, and adverse effects of this drug.
Document emailed within 1 workday
Related Documents
Ebell, M.H. 2005: Choosing between warfarin (Coumadin) and aspirin therapy for patients with atrial fibrillation American Family Physician 71(12): 2348-2350Carroll, W.E.; Jackson, R.D. 1999: Modified anticoagulant therapy factor and international normalized ratio in patients in an unstable coagulation state with respect to warfarin therapy Research Communications in Molecular Pathology and Pharmacology 105(3): 262-270
Pattacini, C.; Manotti, C.; Pini, M.; Quintavalla, R.; Dettori, A.G. 1994: A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol) Thrombosis and Haemostasis 71(2): 188-191
Marutaka, M.; Kubota, Y.; Yoshida, R.; Orita, Y. 2009: Difficult management of warfarin anticoagulant therapy due to S-1 administration for gastric cancer--report of a case Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(9): 1561-1563
Suwanawiboon, B.; Kongtim, P.; Chinthammitr, Y.; Ruchutrakool, T.; Wanachiwanawin, W. 2011: The efficacy of 3-mg warfarin initiating dose in adult Thai patients, who required long-term anticoagulant therapy Journal of the Medical Association of Thailand 94(Suppl 1): S225-S231
Rodríguez-Vélez, R.án.; Ortiz-Rivera, O.J.; Bower, B.; Gorowski, K.; Windemuth, A.; Villagra, D.; Kocherla, M.; Seip, R.L.; D'Agostino, D.; Vergara, C.; Ruaño, G.; Duconge, J. 2010: Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing Puerto Rico Health Sciences Journal 29(4): 402-408
Davidovich, I.M.; Sirotin, B.Z.; Parshina, T.A. 1999: Effects of sodium ethamsylate on anticoagulant and anti-aggregation activity of vascular endothelium in hemorrhagic fever patients with renal syndrome Terapevticheskii Arkhiv 71(6): 49-53
Heine, H.; Schmidt, H.; Mach, H.; Jaruszewski, H. 1971: Anticoagulant therapy and prophylaxis in arterial vascular diseases Das Deutsche Gesundheitswesen 26(19): 861-868
Tazza, L.; Mandolfo, S.; Carbonari, L.; Forneris, G.; Di Dio, M.; Palumbo, R.; Gallieni, M.; Bonforte, G.; Carnabuci, A.; Cavatorta, F.; Aloisi, M.; Galli, F. 2010: Vascular access for hemodialysis: recommendations of the Vascular Access Study Group of the Italian Society of Nephrology Giornale italiano di nefrologia: organo ufficiale della Societa italiana di nefrologia 27(5): 508-511
Guliamov, K.G. 1974: Effect of anticoagulant therapy on vascular permeability in patients with ischemic heart disease Terapevticheskii Arkhiv 46(9): 75-80
Davis, L.J.; Kayser, S.R.; Hubsher, J.; Williams, R.L. 1984: Effect of oxaprozin on the steady-state anticoagulant activity of warfarin Clinical Pharmacy 3(3): 295-297
Yang, P.; Wu, Q.-H.; Luo, X.-Y.; Kou, L.; Chen, Z.; Zhang, Y.-Y.; Zhou, H. 2009: The study of Chinese optimal anticoagulant range of warfarin for venous thromboembolism Zhonghua Yi Xue Za Zhi 89(25): 1762-1765
Amián, A.; Rodríguez, J.N.; Muñiz, R.; Diéguez, J.C.; Moreno, M.V.; Quesada, J.A.; Cañavate, M.; Fernández-Jurado, A.; Martino, M.L.; Prados, D. 1996: Comparative study of the stability of oral anticoagulant treatments (warfarin vs acenocoumarol) Sangre 41(1): 9-11
Levy, G.; O'Reilly, R.A.; Wingard, L.B. 1974: Relationship between the kinetics of the anticoagulant effects of racemic warfarin and its individual enantiomers in man Research Communications in Chemical Pathology and Pharmacology 7(2): 359-365
Islam, M.S.; Islam, M.A.; Azad, A.K.; Banerjee, S.K.; Ahmed, C.M.; Haque, H.; Ahmed, M.K.; Rumki, R.S.; Mahmood, M.; Rashid, F.B. 2016: Use of Anticoagulant Warfarin in Patients Presenting with Atrial Fibrillation in a Tertiary Level Hospital Mymensingh Medical Journal: Mmj 25(3): 523-529
Strain, J.; Templeton, K. 2013: Is Apixaban (Eliquis) the "ideal" anticoagulant to replace warfarin for stroke prevention in atrial fibrillation? South Dakota Medicine: the Journal of the South Dakota State Medical Association 66(1): 20-21
Olteanu, H.; Downes, K.A.; Patel, J.; Praprotnik, D.; Sarode, R. 2009: Warfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell’s Viper Venom Time Clinical Laboratory 55(3-4): 138-142
Palareti, G. 1996: Anticoagulant therapy in patients with atrial fibrillation: the experience of the Centers of Surveillance. Study group of the "Italian Study on Complications of Oral Anticoagulant Therapy" (ISCOAT) Annali Italiani di Medicina Interna: Organo Ufficiale Della Societa Italiana di Medicina Interna 11(Suppl 2): 18s-20s
Vanhaelen, M.; Vanhaelen-Fastré, R. 1978: Stability of anticoagulant derivatives of 4-hydroxycoumarin. II. Structure of the principal degradation products of phenprocoumin, Clocoumarol, warfarin and acenocoumarin Pharmaceutica Acta Helvetiae 53(8): 221-230
Sychev, D.A.; Antonov, I.M.; Ignat'ev, I.V.; Naumova, I.V.; Dmitriev, V.A.; Kropacheva, E.S.; Dobrovol'skiĭ, O.B.; Panchenko, E.P.; Tashenova, I.A.; Kukes, V.G. 2010: Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study Kardiologiia 50(5): 42-46